Non-Melanoma Skin Cancer Market Size 2024-2028
The non-melanoma skin cancer market size is forecast to increase by USD 136.9 million at a CAGR of 4.5% between 2023 and 2028.
- The non-melanoma skin cancer (NMSC) market is experiencing significant growth due to the increasing incidence of this type of cancer. NMSC is the most common form of cancer, with over three million cases diagnosed annually worldwide. The market is facing a challenge due to the lack of drugs in the pipeline for NMSC treatment. This trend is expected to continue, as current treatments such as surgical excision and Mohs micrographic surgery have limitations and may leave scars or require multiple procedures. Healthcare services are playing a critical role in addressing this issue by improving early detection, offering advanced treatment options, and providing patient support throughout the recovery process. Additionally, the aging population and rising awareness about cosmetic skin care are contributing to the market's growth. The market analysis report provides an in-depth analysis of these trends and growth factors, offering valuable insights for stakeholders In the healthcare industry.
What will be the Size of the Non-Melanoma Skin Cancer Market During the Forecast Period?
- The market encompasses a range of conditions, including basal cell carcinoma and squamous cell carcinoma. These forms of cancer are primarily caused by sun exposure, resulting in symptoms such as scaly surfaces, red patches, sores, moles, or warts. Treatment modalities include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, and electrodesiccation. Mohs surgery, a specialized form of surgery, is increasingly utilized for high-risk occurrences due to its ability to preserve healthy tissue.
- Advanced treatments, such as Vismodegib, offer promising alternatives for patients with recurrent or metastatic disease. The market is driven by the increasing prevalence of sun exposure-related injuries and the growing aging population. Despite advancements in treatment options, the risk of recurrence remains a significant concern, necessitating ongoing research and innovation.
How is this Non-Melanoma Skin Cancer Industry segmented and which is the largest segment?
The non-melanoma skin cancer industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Type
- BCC
- SCC
- Geography
- North America
- Canada
- US
- Europe
- Germany
- UK
- Asia
- China
- Japan
- Rest of World (ROW)
- North America
By Type Insights
- The bcc segment is estimated to witness significant growth during the forecast period.
Non-Melanoma Skin Cancer (NMSC), primarily comprised of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), accounts for a significant portion of cancer occurrences worldwide. BCC, responsible for approximately 80% of NMSC, has seen an annual growth rate of 2% In the US and 5% in Europe. In the Asia Pacific region, Australia holds the highest incidence of BCC among individuals aged 70. Despite a low mortality rate of approximately 0.05%, BCCs can result in disfiguring body alterations. Surgical treatments, including Mohs surgery, cryosurgery, and electrodesiccation, are common interventions. Radiation therapy, photodynamic therapy, and topical therapies also serve as alternative treatment methods.
Get a glance at the Non-Melanoma Skin Cancer Industry report of share of various segments Request Free Sample
The BCC segment was valued at USD 410.20 million in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
- North America is estimated to contribute 29% to the growth of the global market during the forecast period.
Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
Non-Melanoma Skin Cancer (NMSC), comprised primarily of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), is a significant health concern In the US, accounting for approximately 35-45% of all cancers among Caucasians. NMSC is the most common cancer type In the US, with BCC being the most prevalent skin cancer subtype. Treatment modalities for NMSC include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, electrodesiccation, Mohs surgery, Vismodegib for advanced cases, and chemotherapy for metastasis. Risk factors for NMSC include sun exposure, sunburns, radiation exposure, inflammation, injury, and the presence of skin growths such as bumps, moles, red patches, sores, moles, warts, and recurrence.
Market Dynamics
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise In the adoption of Non-Melanoma Skin Cancer Industry?
NMSC coverage and support is the key driver of the market.
- Non-Melanoma Skin Cancer (NMSC) is a significant health concern, with Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) being the most common types. Treatment options include surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, and electrodesiccation. Surgery, such as Mohs surgery, is a popular choice due to its high success rate and ability to preserve healthy tissue. However, pharmacotherapy approaches, like Vismodegib, are less preferred due to the need for extensive evaluation and multiple physician visits. The cost of NMSC treatment includes diagnosis, destruction, excision, repair, facility fees, pathology, and peripheral costs. Most payers and Medicare cover surgery and certain pharmacotherapy approaches based on the severity and location of the tumors.
- Risk factors for NMSC include sun exposure, sunburns, radiation exposure, inflammation, injury, and the presence of moles, bumps, scaly surfaces, red patches, sores, moles, warts, and recurrence. High-risk individuals may require advanced treatments from a multidisciplinary medical team. Symptoms of NMSC can include a light pink, white, or waxy appearance, pearly appearance, or dark flesh tone, depending on the type and severity. Early detection and treatment are crucial to prevent metastasis and improve outcomes.
What are the market trends shaping the Non-Melanoma Skin Cancer Industry?
Increasing incidence of NMSC is the upcoming market trend.
- Non-Melanoma Skin Cancer (NMSC) is the most prevalent malignancy worldwide, causing significant morbidity, costs, and a comparatively small but notable mortality rate. According to US national databases, the incidence of NMSC has been on the rise, with a 100% increase among Medicare beneficiaries from 1992 to 2012 and a 35% increase In the general population between 2006 and 2019. The two main types of NMSC are Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). These cancers manifest as various growths, including bumps, scaly surfaces, red patches, and moles, with symptoms such as inflammation, soreness, and changes in tissue appearance, such as a mole becoming larger, darker, or developing a pearly or waxy appearance.
- Risk factors for NMSC include sun exposure, sunburns, radiation exposure, injury, and certain medications. BCC typically grows slowly and has a low risk of metastasis, while SCC can grow rapidly and has a higher risk of metastasis. Treatment options include surgery (Mohs surgery, electrodesiccation, cryosurgery), radiation therapy, photodynamic therapy, and topical therapies (Vismodegib, chemotherapy). A multidisciplinary medical team is often involved In the diagnosis and treatment process. It is crucial for individuals to monitor their skin for any suspicious growths or changes and consult a doctor for proper evaluation and treatment.
What challenges does the Non-Melanoma Skin Cancer Industry face during its growth?
Lack of drugs in pipeline for NMSC is a key challenge affecting the industry growth.
- Non-Melanoma Skin Cancer (NMSC), including Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), poses a significant health concern. According to studies, NMSC accounts for over 90% of all skin cancer occurrences. BCC manifests as a skin growth with a pearly or waxy appearance, while SCC presents as a red patch, sore, bump, or scaly surface. Risk factors include sun exposure, sunburns, radiation exposure, inflammation, injury, and the presence of moles or warts. The treatment landscape for NMSC includes surgery, radiation therapy, photodynamic therapy, topical therapies, cryosurgery, and electrodesiccation. For advanced cases, Mohs surgery, Vismodegib, chemotherapy, and targeted therapies are under investigation.
- These drugs, such as Cetuximab and Erlotinib, target the epidermal growth factor receptor (EGFR) proteins found in cancer cells. The market for NMSC drugs is relatively small due to limited R&D investment. However, ongoing research focuses on developing novel targeted therapies for advanced SCC. A multidisciplinary medical team is crucial for effective diagnosis and treatment. Symptoms like tissue damage, recurrence, and metastasis necessitate prompt attention from a doctor for proper procedure and advanced treatment.
Exclusive Customer Landscape
The non-melanoma skin cancer market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the non-melanoma skin cancer market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, non-melanoma skin cancer market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- 3M Co.
- Almirall SA
- Amgen Inc.
- Bausch Health Companies Inc.
- Bristol Myers Squibb Co.
- Elekta AB
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- iCAD Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sensus Healthcare Inc.
- Sun Pharmaceutical Industries Ltd.
- Varian Medical Systems Inc.
- Viatris Inc.
- Vidac Pharma
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Research Analyst Overview
Non-melanoma skin cancer refers to a group of malignant conditions that originate In the squamous and basal cells of the skin, excluding melanoma. These cancers are characterized by various presentations, including bumps, scaly surfaces, red patches, and sore or inflamed areas. Basal cell carcinoma and squamous cell carcinoma are the most common types, accounting for over 95% of non-melanoma skin cancers. Basal cell carcinoma often appears as a shiny, pearly, or waxy bump, while squamous cell carcinoma can manifest as a scaly, red patch or a sore that fails to heal. Risk factors for both types include prolonged sun exposure, sunburns, radiation exposure, and certain inflammatory conditions.
In addition, the primary treatment modalities for non-melanoma skin cancers include surgery, radiation therapy, and topical therapies. Surgery, such as Mohs micrographic surgery, electrodesiccation, and cryosurgery, is often the preferred choice for removing visible tumors. Radiation therapy is an advanced treatment option for larger tumors or those located in difficult-to-reach areas. Technological advances such as Artificial Intelligence and machine learning are also contributing to the market growth. Topical therapies, like imiquimod and 5-fluorouracil, are used for superficial lesions. Photodynamic therapy is another treatment modality that involves the use of a photosensitizing agent and light to destroy cancer cells. Vismodegib, a hedgehog pathway inhibitor, is a systemic therapy used for advanced basal cell carcinoma. The risk of metastasis is generally low for non-melanoma skin cancers, but high-risk cases may require a multidisciplinary team approach involving dermatologists, surgeons, and medical oncologists.
Furthermore, recurrence is a concern for some patients, especially those with a history of multiple skin cancers or risk factors. Early detection and timely treatment are crucial for managing non-melanoma skin cancers effectively. Regular self-examinations and annual skin checks by a healthcare professional are recommended for individuals with a higher risk of developing these conditions. Non-melanoma skin cancers can occur in any part of the body, including the eyes. Symptoms may include a change in the size, shape, color, or feel of a mole or skin growth, a sore that does not heal, or a new growth on the skin. Telemedicine is increasingly being utilized to support early detection and follow-up care, allowing patients to consult healthcare professionals remotely, especially in areas with limited access to specialized care. This service offers convenience and timely intervention, further enhancing the management of non-melanoma skin cancers.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
145 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
|
Market growth 2024-2028 |
USD 136.9 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.22 |
|
Key countries |
US, Canada, UK, Germany, Japan, and China |
|
Competitive landscape |
Leading Companies, market growth and forecasting, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Non-Melanoma Skin Cancer Market Research and Growth Report?
- CAGR of the Non-Melanoma Skin Cancer industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the non-melanoma skin cancer market growth of industry companies
We can help! Our analysts can customize this non-melanoma skin cancer market research report to meet your requirements.